DPP4 and diabetes mellitus: Both glucagon-like peptide-1 (GLP-1) receptor agonist and dipeptidyl peptidase 4 (DPP-4) inhibitors enhance incretin levels, which inhibit glucagon release, which in turn, increases insulin secretion, as a class of oral hypoglycemics used to treat diabetes mellitus type 2.